Replies to post #125016 on Biotech Values

[DewDiligence]

"Basically the CVD field got into this 'megatrial' world, enrolling tens of thousands patients testing a drug that would be good for all people—things like statins—and it kind of got stuck in this approach," says Topol. "We see this now with the anticoagulants—apixaban and dabigatran—and all the -prils and -sartans. That mentality, that strategy, just isn't sustainable, because the drug companies don't want to go there anymore."

Dr. Topol may be overstating his case. Xarelto, Eliquis, and Pradaxa figure to be three brand new blockbuster products.

[DewDiligence]

…sales of drugs targeting the cardiovascular system would garner, on average, $45.6 million per product per year.

I suspect they are talking about the median value rather than the mean. $45.86M sounds much too low to be the mean.

[DewDiligence]

Related drug-development factoids reside in the following posts:

#msg-59909806 Headline story on BIO’s study
#msg-60339665 Phase-transition probabilities (overall database)
#msg-60340131 Phase-transition probabilities (lead vs secondary indications)
#msg-60340768 Success rates in oncology

Regards, Dew